REG-ICER — Semaglutide and Tirzepatide for Obesity (Final Evidence Report)

[DRAFT — authored 2026-04-19. URL, dates, and key figures web-verified 2026-04-19.]

Source

Institute for Clinical and Economic Review (ICER). Semaglutide and Tirzepatide for Obesity: Effectiveness and Value.

Revised Evidence Report: October 29, 2025
Final Evidence Report: December 16, 2025 (with independent-committee voting outcomes and Policy Recommendations)

External URLs:

Phase 1 manifest note: Manifest cited this as "ICER October 2025 Final Evidence Report." Web-verification 2026-04-19 disambiguates: the October 29, 2025 document is the Revised Evidence Report; the Final Evidence Report was published December 16, 2025. The per-QALY cost-effectiveness figures reported in the manifest ($53,400 tirzepatide; $61,400 injectable semaglutide; $69,300 oral semaglutide) are ICER-generated within the report. The health-benefit price benchmark ranges verified below differ slightly from the manifest's stated $9,100-$15,800 envelope — the verified ranges split benchmarks by agent/formulation.

Scope

ICER assessed the comparative clinical effectiveness and long-term value of:

Semaglutide (injectable) — Wegovy 2.4 mg weekly SC
Oral semaglutide — a higher-dose oral formulation pending approval (OASIS-range doses)
Tirzepatide — Zepbound (5-15 mg weekly SC)

All three were evaluated as adjunct to lifestyle modification for chronic weight management in adults with obesity.

Key Findings

Clinical Effectiveness

Mean difference in weight loss vs placebo (from the pooled / re-synthesized evidence base):

Tirzepatide: -17.8%
Injectable semaglutide: -13.1%
Oral semaglutide: -11.4%

Injectable semaglutide and tirzepatide were also associated with improvements in obesity-related complications:

Injectable semaglutide: Knee osteoarthritis, MASH, HFpEF, reduced incident diabetes, CKD
Tirzepatide: Obstructive sleep apnea and additional metabolic benefits per SURMOUNT program

Independent Committee Voting (Final Report, December 16, 2025)

The independent committee voted unanimously on positive net health benefit for all three treatments.

Cost-Effectiveness Thresholds

Majority of panelists found that, at current pricing, both injectable semaglutide and oral semaglutide as add-on therapies to lifestyle modification represent "high" long-term value for money, as did tirzepatide — acknowledging both the clinical benefit magnitude and current pricing.

ICER Health Benefit Price Benchmarks

ICER-calculated annual price ranges to achieve cost-effectiveness at conventional QALY thresholds:

Injectable semaglutide: $9,100-$12,500
Oral semaglutide: $8,300-$11,400
Tirzepatide: $11,700-$16,100

Budget-Impact Concern

Despite individual-patient value, the very large population appropriate for treatment creates important budget-impact considerations for payers — a recurring theme across the final report and policy recommendations.

Clinical Relevance

ICER 2025 is the authoritative independent value assessment of semaglutide and tirzepatide in obesity care in the United States. Key teaching points:

Value assessments are favorable for all three agents at or near current pricing — a departure from several prior cost-effectiveness analyses (e.g., Hwang 2025 JAMA Health Forum) that found these agents exceed the $100,000/QALY threshold at current net prices. The difference reflects ICER's assumptions on durability, comorbidity-prevention value, and price-concession modeling.
Price benchmark ranges are a useful anchor for payer and practice negotiations and for patient conversations about cost positioning.
Budget-impact problem is separate from value-per-patient. Even agents with favorable per-patient value can stress budgets when the treated population is very large.
Oral semaglutide's benchmark is lower than injectable — reflecting somewhat smaller weight-loss effect in the modeled scenarios.

Teaching implications:

Lesson 5.4 cost-of-care framing should contrast ICER's favorable value verdict with the Hwang JAMA Health Forum finding that at current net prices neither agent meets $100,000/QALY without substantial discount
Cost-of-Care Analysis clinical reference should cite ICER, Hwang, and the Betensky knee-OA analysis as the triangulated economic-evaluation landscape

Linked Peptides

Related References

PMID-40085108 – Hwang JAMA Health Forum Lifetime Cost-Effectiveness (complementary model; different conclusion at current net prices)
PMID-40953447 – Betensky Knee OA Cost-Effectiveness (indication-specific cost-effectiveness analysis)

Orchestrator Notes

URL, dates, benchmark figures web-verified 2026-04-19.
Revised Evidence Report October 29, 2025; Final Evidence Report December 16, 2025 — manifest's "October 2025 Final" was imprecise; noted above.
Primary economic-evaluation anchor for Cost-of-Care Analysis clinical reference and Lesson 5.4 cost-of-care framing.

REG-ICER-Obesity-2025 – ICER Final Evidence Report Semaglutide Tirzepatide